Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03459846
Title A Phase II Study of Durvalumab and Olaparib Compared to Durvalumab in Patients With Advanced, Cisplatin Ineligible Bladder Cancer. (BAYOU)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Durvalumab + Olaparib

Durvalumab

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Research Site Birmingham Alabama 35294 United States Details
Research Site Goodyear Arizona 85338 United States Details
Research Site Fort Myers Florida 33901 United States Details
Research Site Saint Petersburg Florida 33705 United States Details
Research Site Tampa Florida 33612 United States Details
Research Site Louisville Kentucky 40202 United States Details
Research Site Bronx New York 10461 United States Details
Research Site Lake Success New York 11042 United States Details
Research Site New York New York 10065 United States Details
Research Site Philadelphia Pennsylvania 19124 United States Details
Research Site Nashville Tennessee 37232 United States Details
Research Site Tacoma Washington 98405 United States Details
Research Site Hamilton Ontario L8V 5C2 Canada Details
Research Site Newmarket Ontario L3Y 2P9 Canada Details
Research Site Sudbury Ontario P3E 5J1 Canada Details
Research Site Toronto Ontario M5G 2M9 Canada Details
Research Site Montreal Quebec H3T 1E2 Canada Details
Research Site Incheon 21565 Korea, Republic of Details
Research Site Seoul 02841 Korea, Republic of Details
Research Site Seoul 03722 Korea, Republic of Details
Research Site Seoul 05505 Korea, Republic of Details
Research Site Seoul 135-710 Korea, Republic of Details
Research Site Moscow 105077 Russian Federation Details
Research Site Moscow 125367 Russian Federation Details
Research Site Novosibirsk 630108 Russian Federation Details
Research Site Omsk 644013 Russian Federation Details
Research Site Saint Petersburg 195271 Russian Federation Details
Research Site St. Petersburg 194354 Russian Federation Details
Research Site St. Petersburg 199178 Russian Federation Details
Research Site Barcelona 08035 Spain Details
Research Site Barcelona 08036 Spain Details
Research Site Madrid 28041 Spain Details
Research Site Málaga 29010 Spain Details
Research Site Santiago de Compostela 15706 Spain Details
Research Site Kaohsiung 807 Taiwan Details
Research Site Kaohsiung Taiwan Details
Research Site Taichung 40705 Taiwan Details
Research Site Tainan 704 Taiwan Details
Research Site Taipei 10002 Taiwan Details
Research Site Taipei 104 Taiwan Details
Research Site Taipei 112 Taiwan Details
Research Site Taoyuan City 333 Taiwan Details
Research Site Hanoi 100000 Vietnam Details
Research Site Ho Chi Minh 700000 Vietnam Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field